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Abstract 
Objectives 
Mycobacterium chimaera infection following cardiac surgery, due to contaminated 
cardiopulmonary bypass heater-cooler units, has been reported worldwide. However, 
the spectrum of clinical disease remains poorly understood. To address this, we report 
the clinical and laboratory features, treatment and outcome of the first 30 UK cases. 
 
Methods 
Case note review was performed for cases identified retrospectively through outbreak 
investigations and prospectively through on-going surveillance. Case definition was 
Mycobacterium chimaera detected in any clinical specimen, history of cardiothoracic 
surgery with cardiopulmonary bypass, and compatible clinical presentation.  
 
Results 
Thirty patients were identified (28 with prosthetic material) exhibiting a spectrum of 
disease including prosthetic valve endocarditis (14/30), sternal wound infection 
(2/30), aortic graft infection (4/30), and disseminated (non-cardiac) disease (10/30).  
Patients presented a median of 14 months post surgery (maximum 5 years) most 
commonly complaining of fever and weight loss. Investigations frequently revealed 
lymphopenia, thrombocytopenia, liver cholestasis and non-necrotising granulomatous 
inflammation. Diagnostic sensitivity for a single mycobacterial blood culture was 
68% but increased if multiple samples were sent. 27 patients started macrolide-based 
combination treatment and 14 had further surgery. To date, 18 patients have died 
(60%) a median of 30 months (IQR 20-39) after initial surgery. Survival analysis 
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identified younger age, mitral valve surgery, mechanical valve replacement, higher 
serum sodium concentration and lower CRP as factors associated with better survival. 
 
Conclusions 
Mycobacterium chimaera infection following cardiac surgery is associated with a 
wide spectrum of disease. The diagnosis should be considered in all patients who 
develop an unexplained illness following cardiac surgery. 
 
Funding 
This study was funded by Public Health England  
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Introduction 
There is now widespread recognition of the global Mycobacterium chimaera outbreak 
associated with surgery on cardiopulmonary bypass (1-5). Contaminated heater-cooler 
units (HCU) have been identified as the likely source resulting in aerosolisation of M. 
chimaera into the operating theatre environment and direct contamination of the 
surgical field and/or prosthetic material (6-8). Phylogenetic analysis of sequenced M. 
chimaera strains from patients and HCUs has demonstrated strong clustering 
suggesting a point source outbreak likely originating during manufacture (3,4,9).  
 
The spectrum of disease associated with M. chimaera remains poorly understood. 
Case reports have described both prosthetic valve endocarditis (PVE) and 
disseminated disease (2,10,11), with significant diagnostic delay and poor outcome 
(2,7). Given the long incubation period and unknown number of exposures it is vital 
that clinicians are well informed regarding the wide range of pathology associated 
with M. chimaera infection. Here we report the clinical, laboratory, 
echocardiographic and radiological features of the first 30 cases identified in the UK, 
along with outcome data and prognostic markers.  
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Methods 
Case identification 
Cases were identified during a UK national outbreak investigation co-ordinated by 
Public Health England (PHE),[7]. PHE has approval from the Confidentiality 
Advisory Group of the Health Research Authority for the processing of confidential 
patient information through its devolved responsibility under regulation 3 of section 
251 of the NHS Act 2006.  
 
Retrospective cases were identified by cross-referencing national mycobacterial 
reference service data with National Health Service (NHS) data for surgery with 
cardiopulmonary bypass or extracorporeal membrane oxygenation using unique 
patient NHS numbers. Prospective cases were identified through diagnostic laboratory 
reporting.  A case was defined as: detection of M. chimaera in any clinical specimen, 
prior cardiothoracic surgery involving cardiopulmonary bypass, and a compatible 
clinical presentation (e.g. endocarditis, surgical site or disseminated infection; isolated 
pulmonary infection was excluded).  A maximum incubation period of 4 years was 
initially used for retrospective case finding but extended to 10 years for prospective 
surveillance in light of subsequent reports. 
 
Mycobacterial identification 
Mycobacterial cultures provisionally identified as M. intracellulare by line probe 
assay (GenoType Mycobacterium CM, HAIN Lifescience) were identified as M. 
chimaera by internal transcribed spacer (ITS) sequencing and additionally in 18 
patients by whole-genome sequencing (WGS) (12). WGS was performed using an 
Illumina (San Diego, California) MiSeq sequencing platform that identified 
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mycobacterial species using a gene presence or absence algorithm (compared against 
a catalogue of 169 sequenced mycobacterial strains) (7,13). 16s PCR with DNA 
sequence analysis was performed in-house following a previously detailed method 
(14). Clarithromycin sensitivity testing was performed at clinician’s request using 
either standard broth microdilution with AIM Sensititre® plates (Trek Diagnostics 
Systems) or by direct agar proportion method on Lowenstein-Jensen slope media 
(15).  
 
Data collection  
Case note review was performed by local clinicians detailing clinical, laboratory and 
radiological findings, treatment, clinical outcome (alive/dead) and date of death. 
Outcome was re-checked on 30th September 2017 when the database was closed. 
Echocardiography reports were considered diagnostic of PVE if they met Duke major 
criteria (16). Radiological reports were independently categorised by two 
investigators with differences resolved through discussion.  
 
Statistical analysis 
Database creation and management was conducted using EpiData Manager and 
EntryClient (v4.0.1.45, EpiData, Denmark). Clinical data were double-entered by two 
independent investigators. Chi-squared testing was performed to compare frequency 
of symptoms between clinical groups; cox proportional hazards modelling was 
performed to assess risk factors linked to all-cause mortality from date of surgery. 
STATA (v14.2, StataCorp, USA) was used for all statistical analysis. 
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Results 
Patients 
The median age at diagnosis was 65 years (range 8-82); 23 (77%) were male. 
Comorbidities included ischaemic heart disease (10/30), hypertension (6/30), and 
diabetes (7/30). Significant immune suppression was present in one patient. All 
patients had negative HIV serology. Cardiac surgery was performed in 17 different 
cardiac centres in the UK between 2007 and 2015 as detailed in Table 1. A marked 
increase in cases was observed in patients who had surgery after 2011 (Figure 1). 
Stöckhert 3T HCUs were in use in all centres during the relevant time periods. Earlier 
investigations isolated M. chimaera from 17 out of 35 3T HCUs sampled (7).  
 
Clinical features 
The median time between surgery and developing symptoms was 14.5 months (IQR 
9.8-19.4) but ranged from 6 weeks to five years; 80% of patients became unwell 
within 2 years of surgery (Figure 2). The median duration of symptoms was 7 weeks 
(IQR 4-15) but the longest was one year. Unexplained fever was the most common 
presentation (80%); five patients had signs of chronic sternal wound infection (Table 
2). PVE was diagnosed in 14 patients and aortic graft infection in four, 10 had 
disseminated (non-cardiac) infection affecting a variety of organs (liver, spleen, bone 
marrow, spine, skin, bone) and 2 had isolated sternal wound infection. Patients with 
PVE and disseminated disease were significantly more likely to present with fever 
(P=.003), while aortic graft and sternal wound infections more likely to present with 
chest pain (P<.001). 
 
Laboratory tests 
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Twenty-three patients (77%) had abnormal full blood counts (FBC): lymphopenia 
(<1x109/L) was present in 19 (63%) and thrombocytopenia (<150x109/L) in 14 (47%) 
(Table 2). Deranged liver function tests (LFTs) were also common and typically 
displayed a cholestatic pattern with raised alkaline phosphatase (>130 IU/L), in 21/30 
patients (70%). Only three patients had both normal FBC and LFTs at presentation 
(all with sternal wound infections) and only one patient at the time of diagnosis. CD4 
counts were measured in four patients: absolute counts were below normal (range 
263-390/L) but the percentage was preserved, consistent with a generalised 
reduction in all lymphocytes.  
 
Mycobacteriology 
The median time between presentation to hospital and microbiological diagnosis was 
10 weeks (range 2-100). M. chimaera was cultured from a range of fluids/tissues, the 
most common being blood and urine (Table 3).  Prior to initiation of therapy the 
overall diagnostic sensitivity for a single mycobacterial blood culture was 68% (28/41 
samples positive) but decreased to 34% (11/32) once treatment started. Diagnostic 
yield was increased with multiple samples: all patients with at least two mycobacterial 
blood cultures isolated M. chimaera from at least one sample (Supplementary Table 
1). Blood cultures were negative in four patients when taken immediately after 
revision valve surgery. M. chimaera was isolated from explanted prosthetic 
valves/cardiac tissue from all 10 patients who underwent repeat surgery or post 
mortem examination (Table 3). Five of these 10 were taking anti-mycobacterial 
therapy at the time of sampling (median 6 months, range 1-14 months). M. chimaera 
was cultured from sternal tissue in all five patients who presented with a chronic 
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sternal wound infection. No macrolide resistance was detected in 15 patients at 
baseline, two patients who were failing treatment and on one patient who relapsed.  
 
Echocardiography  
Prosthetic valve endocarditis (PVE) was diagnosed in 11/29 (38%) patients who 
underwent echocardiography during diagnostic workup (5/24 had positive 
transthoracic echocardiography [TTE]; 10/22 had positive transoesophageal 
echocardiography [TOE]) (Supplementary Table 2). Major echocardiographic 
findings included vegetations (7/29), aortic root abscess (5/29) and valvular 
regurgitation (4/29). TTE had a sensitivity of 33% and specificity of 88% compared 
to TOE in the 17 patients who had both investigations performed. Three patients with 
normal initial echocardiography were later diagnosed with PVE by either follow-up 
TOE or post mortem examination.  
 
Radiology 
Computerised tomography (CT) scanning commonly revealed splenomegaly (14/26) 
and pulmonary consolidation/infiltrate (10/26); other important findings included 
mediastinal/aortic graft infection (4/26) and fluid around the aortic root (5/26) 
(Supplementary Table 3). Ten patients had a positron emission tomography (PET)-
CT scan performed. This provided additional evidence of aortic graft infection in 3 
patients in whom standard CT scanning had been equivocal.  
 
Histopathology and post mortem examinations 
Non-caeseating granulomatous inflammation was observed in 15 out of 19 patients 
who underwent biopsy. The most commonly biopsied tissues included liver (7/8 
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patients with granulomas) and bone marrow (7/10 with granulomas) but in some the 
changes were scanty. Post mortem examination was performed in four patients and 
revealed varying degrees of granulomatous inflammation and embolic disease 
affecting the heart, lungs, kidneys, liver, spleen, bone marrow, vertebrae, sternum and 
brain; PVE was noted in two patients.  
 
Treatment  
27 patients started combination therapy (three died prior) comprising a macrolide 
(clarithromycin n=23; azithromycin n=4), rifamycin (rifampicin n=18; rifabutin n=8) 
and ethambutol (n=27); additional treatment consisted of intravenous amikacin (n=5) 
and/or quinolone (n=3) (Supplementary Table 4). Eleven patients developed 
significant drug toxicity within the first 6 months including, deranged liver tests, renal 
dysfunction, hearing loss, gastrointestinal upset and hypercalcaemia. Eight patients 
had intensification of treatment with amikacin and/or quinolones.  Interferon-gamma 
was given to three patients but two developed inflammatory reactions. Four received 
corticosteroids without anti-mycobacterial treatment (presumed sarcoidosis) and had 
an initial clinical, biochemical and radiological improvement but eventually 
deteriorated with worsening infection. Fourteen patients underwent further surgery a 
median of 23 months (IQR 17-37) after the original surgery. Operations performed 
included aortic valve replacement (2/14), aortic valve replacement with repair of 
aortic root abscess (6/14), mitral valve repair (1/14), and sternal wound debridement 
(5/14). 30-day survival following repeat surgery was 92%.  
 
Outcome 
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As of 30th September 2017, 18 out of 30 patients had died (60%), a median of 30 
months (IQR 20-39) after initial surgery and 9 months (IQR 2-14) after treatment was 
started. Kaplan-Meier estimates of 5-year survival were 0.45 (95%CI 0.24-0.63) 
(Figure 3). 8 patients remain on treatment (median 19 months, IQR 9-22), two of 
whom are re-treatments after relapsing within a year of treatment cessation. Four 
patients have completed treatment and remain well (median 14 months off treatment; 
range 4-40 months). 
 
An exploratory survival analysis identified younger age, white British ethnicity, 
mitral valve repair, mechanical valve replacement, higher serum sodium 
concentration and lower CRP to be associated with significantly improved survival 
(Supplementary Table 5). No particular treatment was significantly associated with 
improved survival but a non-significant trend towards improved survival was 
observed for patients who underwent further surgery (HR .51, 95% CI .2-1.3, P=.16) 
(Supplementary Figure 1).  
 
Discussion  
This study is largest cohort of cardiac surgery associated M. chimaera infections 
reported to date and provides important information regarding the clinical features, 
laboratory abnormalities, sensitivity of diagnostic tests and prognostic markers. 
Consistent with earlier reports M. chimaera infection was associated with a spectrum 
of disease including PVE, disseminated disease, aortic graft and sternal wound 
infections (2,5,10,17). Diagnosis was frequently delayed and response to treatment 
was poor.  
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Immune suppression was not a required predisposing factor. Although lymphopenia 
was a common finding this was not documented prior to cardiac surgery and is likely 
to be a consequence of infection. Indeed, progressively worsening lymphopenia due 
to lymphocyte apoptosis has been observed in mouse models of disseminated 
Mycobacterium avium (18). All but two patients in the cohort had prosthetic material 
inserted during surgery. These two developed isolated sternal wound infections 
following CABG with no evidence of cardiac or disseminated disease. Given the large 
numbers of CABG procedures performed each year (16,791 procedures/year, UK 
2012) the overall risk for patients undergoing CABG remains extremely low (19). 
However, a report of M. chimaera spondylodiscitis following CABG suggests 
disseminated infection may occasionally occur in the absence of prosthetic material 
(8).  
 
Identifying patients with M. chimaera is difficult due to the insidious onset, non-
specific symptoms and prolonged incubation period. However, splenomegaly, 
abnormal LFTs, cytopenias and granulomatous inflammation were common findings 
and could be used to guide microbiological testing (2,5,10). Fundoscopy may also be 
a helpful diagnostic adjunct given the choroidoretinitis reported here and elsewhere 
(10,11). 
 
Culture of M. chimaera from peripheral blood was the most common method of 
microbiological diagnosis. Sensitivity was increased by sending multiple samples but 
reduced by anti-mycobacterial therapy. The combination of mycobacterial culture and 
16S rRNA gene sequencing of excised cardiac material was positive in all patients in 
whom material was available. This data has informed UK guidance which 
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recommends three mycobacterial blood cultures and early morning urine samples in 
suspected patients, along with mycobacterial culture and 16s PCR testing of tissue or 
valve specimens (20). 
 
Consistent with previous studies in bacterial PVE, TOE was more sensitive than TTE 
in diagnosing M. chimaera PVE (21). However, the later development of PVE in 
patients with an initially normal TOE suggests serial assessment should be 
considered. Aortic graft infections were frequently associated with an overlying 
sternal wound infection and CT, MRI or CT-PET scanning were helpful assessing 
deeper infection/graft involvement. CT-PET has also proved useful elsewhere in the 
diagnosis of M. chimaera spondylodiscitis and PVE (5). 
 
Mortality due to M. chimaera was high (60%) and the estimated 5-year survival of 
45% is markedly worse than that reported from large cardiac surgery outcome studies 
(76-95% 5-year survival) (22,23). Significantly better survival was observed among 
patients who had undergone mitral valve repair compared to aortic valve or root 
surgery. This could be a result of differing areas of prosthetic material available for 
biofilm formation. However, studies in bacterial PVE have not reported such 
differences (24,25).  
 
Optimal treatment for M. chimaera is unknown and guidelines for Mycobacterium 
avium complex (MAC) treatment were followed (26,27). No drug treatment was 
associated with significantly better survival but a non-significant trend was observed 
among patients who underwent repeat surgery. Repeat valve surgery is frequently 
required to cure PVE caused by biofilm-forming organisms (28-30), and a survival 
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benefit has been demonstrated in a meta-analysis of observational studies in bacterial 
PVE (31). Given the known potential of M. chimaera to form biofilms (32), and the 
clear failure in this cohort to sterilise valves with medical treatment alone, it is 
possible that a sustained cure in M. chimaera PVE may not be possible without 
removal of infected material (6,7). However, given the technical difficulties of repeat 
surgery and the inherent risk this may pose to patients, such decisions cannot be taken 
lightly and more outcome data are required before this question can be addressed. 
Studies reporting culture-positivity rates of explanted valves from M. chimaera 
patients will be helpful to inform clinical decision-making. 
 
This study has limitations. It is a small retrospective observational study with low 
statistical power; it is subject to case selection bias and likely underestimates of the 
total case burden. As such, these results should be interpreted with caution and ideally 
verified in larger cohorts. However, it is the largest study of cardiac surgery-
associated Mycobacteria chimaera infection to date and the first to examine 
diagnostic, treatment and prognostic factors. We also report the identification of M. 
chimaera using WGS, a rapid and cost-effective method of mycobacterial diagnostics 
that is increasingly used in UK mycobacterial reference laboratories (13). 
 
Large numbers of patients undergo cardiac surgery every year (UK~150,000) (19). 
Whilst the overall risk to patients remains very low (7), it is likely there are more 
patients who have been infected. Clinicians must remain vigilant and M. chimaera 
infection should be strongly suspected in patients with a history of cardiac surgery 
(especially with prosthetic material) who develop unexplained fevers, weight loss, 
splenomegaly, cytopenias, hepatitis, granulomatous inflammation or chronic sternal 
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wound infections; particular caution should be taken when making a diagnosis of 
sarcoidosis. Efforts are now required to combine international data to better inform 
treatment, particularly the use of additional anti-mycobacterial drugs and the 
indications for repeat valve surgery.  
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Figure 1 – Histogram displaying year of original cardiac surgery for patients 
who developed M. chimaera infection in UK (n=30).  
 
 
 
 
Figure 2 – Violin plot demonstrating the distribution of times between cardiac 
surgery and the development of symptoms, hospital admission and diagnosis of 
M. chimaera infection. Plots comprise a symmetrical kernel-density plot (red) 
showing the full distribution of times with a superimposed boxplot (blue) 
demonstrating the median times with interquartile ranges. Time is quantified in days 
post original cardiac surgery. Vertical height of each plot represents the kernel 
probability density of data.  
 
 
 
 
 
Figure 3 – Kaplan-Meier survival curve illustrating survival after cardiac 
surgery for patients diagnosed with Mycobacterium chimaera infection. Numbers 
at risk are shown below the plot. Shading indicates 95% confidence intervals. Kaplan-
Meier estimate of 5-year survival is 0.45 (95%CI 0.24-0.63). The low numbers of 
patients with follow-up data ≥5 years mean survival estimations after this point 
should be interpreted with caution.  
